Afterloading interstitial implant in head and neck cancer

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Head and neck malignancies pose significant treatment challenges.
• Brachytherapy offers a localized radiation approach for these cancers.
• Iridium-192 (Ir-192) is a commonly used radioisotope for interstitial brachytherapy.

Purpose of the Study:

• To evaluate the efficacy and outcomes of afterloading interstitial iridium-192 brachytherapy for head and neck malignancies.
• To assess local control rates for different tumor stages (T1-T4).
• To determine the feasibility and morbidity of surgical salvage after brachytherapy failure and the outcomes of reirradiation.

Main Methods:

• Seventy-nine patients with head and neck malignancies were treated between February 1974 and November 1975.
• Afterloading interstitial iridium-192 brachytherapy was the primary treatment modality.
• Follow-up included assessment of local control, salvage surgery, and reirradiation outcomes with a minimum of 24 months.

Main Results:

• Local control was achieved in 12 of 13 (92%) T1 and T2 lesions.
• Local control was achieved in 17 of 25 (68%) T3 and T4 lesions.
• Twenty of 41 (49%) reirradiated patients maintained local control.
• Surgical salvage demonstrated low morbidity due to limited external irradiation.

Conclusions:

• Afterloading interstitial iridium-192 brachytherapy is an effective treatment for head and neck malignancies, yielding high local control rates, particularly in early-stage disease.
• The technique allows for effective surgical salvage with low morbidity in cases of treatment failure.
• Reirradiation is a viable option for persistent or recurrent cancers, offering continued local control for a significant proportion of patients.